We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...

Envudeucitinib, another allosteric TYK2 inhibitor, also achieved PASI 75 in 70-75% of patients at 16 weeks and PGA 0/1 status ...

Transaction terms include a 31% premium to 60-day and 42% to 90-day VWAP, with an expected ~$5.8B charge reflected in Q2 and FY 2026 results. Targeting the ABL myristoyl pocket differentiates TERN-701 ...

Brepocitinib significantly boosts global, all secondary dermatomyositis scores in VALOR tr ...

A new comprehensive review is shedding light on the expanding role of focal adhesion kinase (FAK) in cancer biology and its potential as a ...

Merck & Co., Inc. (NYSE:MRK) held an investor event to discuss its planned acquisition of Terns Pharmaceuticals, emphasizing ...

First candidate from Tenvie’s product engine to enter clinical developmentPhase 1 first-in-human study to evaluate single and multiple ascending ...

ORIC Pharma to report combination dose optimization data from phase 1b trial of rinzimetostat in patients with mCRPC: South San Francisco, California Monday, March 30, 2026, 18:00 ...

71.4% and 69.2% of patients treated with zasocitinib achieved a static Physician Global Assessment (sPGA) score of 0/1 versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%) at week 16 (p<0 ...

Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI ...

RAHWAY, N.J., & FOSTER CITY, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a ...